Skip to main content

Advanced Search

Advanced Search

Current Filters

Filter your query

Publication Types

Other

to

Newsletter Article

/

A Drug Costs $272,000 a Year. Not So Fast, Says New York State

A wave of breakthrough drugs is transforming the medical world, offering hope for people with deadly diseases despite their dizzying price tags. But what if it turns out that some of these expensive new drugs don't work that well? That's the quandary over Orkambi, a drug that was approved in 2015 for cystic fibrosis and was only the second ever to address the underlying cause of the genetic disease. Orkambi, which is sold by Vertex Pharmaceuticals, costs $272,000 a year, but has been shown to only modestly help patients. Now, in a case that is being closely watched around the country, New York state health officials have said Orkambi is not worth its price, and are demanding that Vertex give a steeper discount to the state's Medicaid program. The case is the first test of a new law aimed at reining in skyrocketing drug costs in New York's Medicaid program. (Katie Thomas, New York Times)

Publication Details

Date